hapabapa
Exelixis (NASDAQ:EXEL) announced Thursday that the U.S. Food and Drug Administration (FDA) no longer plans to conduct an advisory committee meeting as part of its review of the company’s supplemental New Drug Application for cancer therapy cabozantinib (Cabometyx).
In August, the